ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » RA – Diagnosis, Manifestations, & Outcomes Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM
Abstract Number: 2243
A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2242
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2217
A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity
10:30AM-12:30PM
Abstract Number: 2216
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
10:30AM-12:30PM
Abstract Number: 2224
Age of Onset of Rheumatoid Arthritis and Radiographic Changes
10:30AM-12:30PM
Abstract Number: 2239
Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2232
Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
10:30AM-12:30PM
Abstract Number: 2229
Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination
10:30AM-12:30PM
Abstract Number: 2249
Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry
10:30AM-12:30PM
Abstract Number: 2218
Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2221
Association Between Serum Uric Acid/Serum Creatinine Index and Carotid Plaque in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2219
Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort
10:30AM-12:30PM
Abstract Number: 2248
Association of Integrative Health Practices with Health-Related Quality of Life in Women with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2241
Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry
10:30AM-12:30PM
Abstract Number: 2250
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
10:30AM-12:30PM
Abstract Number: 2245
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
10:30AM-12:30PM
Abstract Number: 2208
Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry
10:30AM-12:30PM
Abstract Number: 2210
Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality
10:30AM-12:30PM
Abstract Number: 2214
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
10:30AM-12:30PM
Abstract Number: 2228
Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2211
Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques
10:30AM-12:30PM
Abstract Number: 2209
Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2233
Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2240
Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2213
Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2220
Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis
10:30AM-12:30PM
Abstract Number: 2222
Primary Lung Involvement in Early Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2247
Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis
10:30AM-12:30PM
Abstract Number: 2234
Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort
10:30AM-12:30PM
Abstract Number: 2236
Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2230
Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2225
Role of Fatigue in Difficult to Treat Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2246
Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial
10:30AM-12:30PM
Abstract Number: 2212
Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort
10:30AM-12:30PM
Abstract Number: 2226
Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2251
Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2237
The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2238
The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status
10:30AM-12:30PM
Abstract Number: 2235
The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2215
Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis
10:30AM-12:30PM
Abstract Number: 2231
Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort
10:30AM-12:30PM
Abstract Number: 2244
Unveiling Synovial Protein Contributions to Serum Inflammation, Disease Activity, and Treatment Outcomes in RA Patients
10:30AM-12:30PM
Abstract Number: 2223
Validation Study in Early Rheumatoid Arthritis Patients of the Spanish Society of Rheumatology (SER)/Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Screening Criteria for Interstitial Lung Disease
10:30AM-12:30PM
Abstract Number: 2227
Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology